Activities
The Evolving Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer: Opportunities for Pharmacists to Optimize Treatment Selection
0290-0000-19-152-H01-P
This article will examine the pathway to anaplastic lymphoma kinase (ALK) therapy resistance mutations in selection of an appropriate ALK inhibitor
2.00
The Role of the Pharmacist With Cholesterol Management: Focusing on New Guidelines and PCSK9 Inhibitors
0290-0000-19-153-H01-P
This activity reviews the new cholesterol guidelines and highlights the role and evidence supporting the use of PCSK9 inhibitors in the treatment of hypercholesterolemia.
2.00
Improving Patient Access to PCSK9 Inhibitors: The Role of the Pharmacist
0290-0000-19-165-H01-P
This on-demand webinar will outline the role of PCSK9 inhibitors in the treatment of hypercholesterolemia including mechanism of action and potential adverse effects.
0.50
Improving Patient Counseling in the Pharmacy Setting: Understanding the Needs of Patients Treated for Depression
0290-0000-19-169-H01-P
This on-demand webinar will explain daily challenges of patients with major depressive disorder (MDD) and the impact on patients’ ability to seek treatment
1.00